232 related articles for article (PubMed ID: 38113273)
1. A distinct isoform of lymphoid enhancer binding factor 1 (LEF1) epigenetically restricts EBV reactivation to maintain viral latency.
Ward BJH; Prasai K; Schaal DL; Wang J; Scott RS
PLoS Pathog; 2023 Dec; 19(12):e1011873. PubMed ID: 38113273
[TBL] [Abstract][Full Text] [Related]
2. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
Dunn LEM; Lu F; Su C; Lieberman PM; Baines JD
J Virol; 2023 Feb; 97(2):e0189422. PubMed ID: 36744959
[TBL] [Abstract][Full Text] [Related]
4. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
5. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
Woellmer A; Arteaga-Salas JM; Hammerschmidt W
PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
[TBL] [Abstract][Full Text] [Related]
6. BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV.
Schaeffner M; Mrozek-Gorska P; Buschle A; Woellmer A; Tagawa T; Cernilogar FM; Schotta G; Krietenstein N; Lieleg C; Korber P; Hammerschmidt W
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30926617
[TBL] [Abstract][Full Text] [Related]
7. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
8. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
[TBL] [Abstract][Full Text] [Related]
9. 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch.
Wille CK; Nawandar DM; Henning AN; Ma S; Oetting KM; Lee D; Lambert P; Johannsen EC; Kenney SC
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7257-65. PubMed ID: 26663912
[TBL] [Abstract][Full Text] [Related]
10. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
11. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.
Ellis AL; Wang Z; Yu X; Mertz JE
J Virol; 2010 Jun; 84(12):6139-52. PubMed ID: 20375168
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
[TBL] [Abstract][Full Text] [Related]
13. PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type.
Lupey-Green LN; Caruso LB; Madzo J; Martin KA; Tan Y; Hulse M; Tempera I
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976663
[TBL] [Abstract][Full Text] [Related]
14. The nuclear lamina binds the EBV genome during latency and regulates viral gene expression.
Caruso LB; Guo R; Keith K; Madzo J; Maestri D; Boyle S; Wasserman J; Kossenkov A; Gewurz BE; Tempera I
PLoS Pathog; 2022 Apr; 18(4):e1010400. PubMed ID: 35421198
[TBL] [Abstract][Full Text] [Related]
15. Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.
Murata T; Sugimoto A; Inagaki T; Yanagi Y; Watanabe T; Sato Y; Kimura H
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960613
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus miR-BHRF1-3 Targets the BZLF1 3'UTR and Regulates the Lytic Cycle.
Fachko DN; Chen Y; Skalsky RL
J Virol; 2022 Feb; 96(4):e0149521. PubMed ID: 34878852
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
18. Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells.
Imai K; Kamio N; Cueno ME; Saito Y; Inoue H; Saito I; Ochiai K
FEBS J; 2014 May; 281(9):2148-58. PubMed ID: 24588869
[TBL] [Abstract][Full Text] [Related]
19. Switching of EBV cycles between latent and lytic states.
Murata T; Tsurumi T
Rev Med Virol; 2014 May; 24(3):142-53. PubMed ID: 24339346
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T
J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
